There are currently 979 clinical trials in San Antonio, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Texas Health Science Center at San Antonio, GSK Investigational Site, Pfizer Investigational Site and Methodist Children's Hospital of South Texas. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)
Recruiting
This is an open-label, multicenter study to evaluate the safety, tolerability, and efficacy of HMPL-523 in adult subjects with ITP.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2024
Locations: Texas Oncology San Antonio Medical Center, San Antonio, Texas
Conditions: Immune Thrombocytopenia, Blood Platelet Disorder, Hematologic Diseases, Purpura, Thrombocytopenic, Purpura, Blood Coagulation Disorder, Thrombotic Microangiopathies, Hemorrhagic Disorders, Autoimmune Diseases, Immune System Diseases, Hemorrhage, Pathologic Processes, Skin Manifestations, Thrombocytopenia, Purpura, Thrombocytopenic, Idiopathic, Primary Immune Thrombocytopenia, ITP - Immune Thrombocytopenia
Pilot Trial Investigating Every Other Day Dosing of Oral Iron in Premature Infants (IQONic)
Recruiting
Study focuses on determining if daily versus every-other-day (EOD) oral iron at the same dose per kilogram per day will achieve similar incidence of iron replete status at 36 weeks post-menstrual age in premature neonates
Gender:
ALL
Ages:
Between 26 weeks and 32 weeks
Trial Updated:
08/13/2024
Locations: CHRISTUS Children's, San Antonio, Texas
Conditions: Very Low Birth Weight Infant, Premature Infants, Anemia of Prematurity, Iron Deficiency, Anaemia in Children, Extremely Low Birth Weight
Rapamycin - Effects on Alzheimer's and Cognitive Health
Recruiting
This study will evaluate the safety, tolerability, and feasibility of 12 month oral rapamycin treatment in older adults with amnestic mild cognitive impairment (aMCI) and early stage Alzheimer's disease (AD).
Gender:
ALL
Ages:
Between 55 years and 89 years
Trial Updated:
08/12/2024
Locations: Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, San Antonio, Texas
Conditions: Mild Cognitive Impairment, Alzheimer Disease
A Study to Evaluate Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects
Recruiting
This is a Phase 3, randomized, open-label, multicenter, study in male and female pediatric subjects (2 years to \<18 years of age) with IDA, or felt by their clinician to be at risk of developing IDA. This study allows for enrollment of subjects with IDA regardless of etiology, except for CKD subjects (pediatric CKD subjects are being studied in a separate ferumoxytol protocol).
Gender:
ALL
Ages:
Between 2 years and 17 years
Trial Updated:
08/09/2024
Locations: Sun Research Institute, San Antonio, Texas
Conditions: Iron Deficiency Anemia
Study of Ciraparantag for Reversal of Anticoagulation Induced by Edoxaban, Apixaban or Rivaroxaban in Healthy Adults
Recruiting
A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ciraparantag for reversal of anticoagulation induced by different anticoagulant drugs in generally healthy adults as measured primarily by an automated coagulometer device.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/09/2024
Locations: ICON Early Phase Services, LLC, San Antonio, Texas
Conditions: Healthy
Erector Spinae Regional Anesthesia for Pain Control
Recruiting
Interventional study to use erector spinae plane block (ESPB) on diagnoses of posterior or lateral rib fractures, vertebral fractures, pancreatitis, pancreatic cancer, renal colic, and back pain for multimodal pain therapy to determine its assistance with pain relief as well as the patient's use of opiates after block completion
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/08/2024
Locations: University Hospital, San Antonio, Texas
Conditions: Pain Management
Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma
Recruiting
This study is designed as a single center, prospective, open label, single-arm therapeutic trial with both surgical and non-surgical cohorts.
Gender:
ALL
Ages:
All
Trial Updated:
08/07/2024
Locations: Mays Cancer Center, UT Health San Antonio, San Antonio, Texas
Conditions: Glioblastoma
Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)
Recruiting
HYPOTHESIS: Impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) have distinct pathophysiologic etiologies. Therefore, therapeutic interventions designed to correct the specific underlying pathogenic abnormalities in IGT and IFG will be required to optimally prevent the progressive beta cell failure and development of overt type 2 diabetes.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/06/2024
Locations: The University of Texas Health Science Center at San Antonio, San Antonio, Texas
Conditions: Diabetes Mellitus, Type 2, Impaired Glucose Tolerance (IGT), Impaired Fasting Glucose (IFG)
BFR Therapy for Post-Op Rehab of ACL Reconstruction With Quadriceps Tendon Autograft
Recruiting
The overall objective of the proposed research is to conduct a prospective, randomized controlled trial to investigate whether the addition of BFR therapy to standard post-operative rehabilitation regimen significantly improves clinical outcomes following anterior cruciate ligament reconstruction (ACLR) standardized with respect to both surgical technique and graft selection. Patients indicated for ACLR will be screened and offered enrollment into this prospective, randomized controlled trial. M... Read More
Gender:
ALL
Ages:
Between 15 years and 45 years
Trial Updated:
08/06/2024
Locations: Brooke Army Medical Center- Clinical Research Center, San Antonio, Texas
Conditions: ACL Injury
A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors
Recruiting
The goal of this clinical trial is to define a safe and effective dose of DM919 for participants with solid tumors The main questions it aims to answer are: What is the safe and effective dose of DM919 when used alone or in combination with pembrolizumab? What cancers can be treated effectively with DM919 alone or in combination with pembrolizumab?? Participants will be asked to attend clinic and be given a intravenous infusion of DM919 or DM-919 in combination with pembrolizumab. They will h... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/04/2024
Locations: NEXT Oncology, San Antonio, Texas
Conditions: Advanced Solid Tumor
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MKND-201 in Healthy Volunteers
Recruiting
MKC-NI-001 is a Phase 1, first-in-human, randomized, double-blind, placebo-controlled study of nintedanib inhalation powder (MNKD-201) in healthy adult volunteers. The trial consists of a Single Ascending Dose (SAD), followed by a Multiple Ascending Dose (MAD) with a primary objective to evaluate the safety, tolerability, and pharmacokinetics (PK) of MNKD-201 compared to placebo in healthy adult participants.
Gender:
ALL
Ages:
Between 40 years and 65 years
Trial Updated:
08/02/2024
Locations: Flourish Research, San Antonio, Texas
Conditions: Healthy Volunteers
Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)
Recruiting
Langerhans Cell Histiocytosis (LCH) is a type of cancer that can damage tissue or cause lesions to form in one or more places in the body. Langerhans cell histiocytosis (LCH) is a cancer that begins in LCH cells (a type of dendritic cell which fights infection). Sometimes there are mutations (changes) in LCH cells as they form. These include mutations of the BRAF gene. These changes may make the LCH cells grow and multiply quickly. This causes LCH cells to build up in certain parts of the body,... Read More
Gender:
ALL
Ages:
21 years and below
Trial Updated:
08/01/2024
Locations: Children's Hospital of San Antonio, San Antonio, Texas
Conditions: Langerhans Cell Histiocytosis